MTST (MetaStat) Ending Cash Position: $0.32 Mil (As of Feb. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MetaStat Ending Cash Position?

MetaStat MTST Ending Cash Position is $0.32 Mil as of Feb. 2018.

MetaStat's Ending Cash Position for the quarter that ended in Feb. 2018 was $0.32 Mil.

MetaStat's quarterly Ending Cash Position declined from Aug. 2017 ($1.73 Mil) to Nov. 2017 ($0.78 Mil) and declined from Nov. 2017 ($0.78 Mil) to Feb. 2018 ($0.32 Mil).

MetaStat's annual Ending Cash Position increased from Feb. 2016 ($0.36 Mil) to Feb. 2017 ($0.78 Mil) but then declined from Feb. 2017 ($0.78 Mil) to Feb. 2018 ($0.32 Mil).

MetaStat Ending Cash Position Related Terms

MetaStat Ending Cash Position Historical Data

* Premium members only.

The historical data trend for MetaStat's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat Ending Cash Position Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 0.26 0.36 0.78 0.32

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 0.15 1.73 0.78 0.32

MetaStat Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

MetaStat's Ending Cash Position for the fiscal year that ended in Feb. 2018 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.783+-0.466
=0.32

MetaStat's Ending Cash Position for the quarter that ended in Feb. 2018 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.78+-0.463
=0.32

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.32 Mil mean?
MetaStat (MTST) has a Ending Cash Position of $0.32 Mil as of Feb. 2018. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on MetaStat and its competitors.
Is MetaStat's Ending Cash Position too high?
MetaStat's current Ending Cash Position is $0.32 Mil.
How does MetaStat's Ending Cash Position compare to OBMP and NSPX?
MetaStat's Ending Cash Position of $0.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on MetaStat and its competitors. MetaStat's current Ending Cash Position is $0.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaStat stock overvalued right now?
MetaStat (MTST) has a current Ending Cash Position of $0.32 Mil. The current Ending Cash Position is $0.32 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For MetaStat (MTST), the current Ending Cash Position is $0.32 Mil as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.